Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Home
About
Overview
Open Source Software
Help
History (1)
Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC.
Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC. Oncologist. 2011; 16(6):886-95.
View in:
PubMed
subject areas
Adult
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung
Combined Modality Therapy
Endpoint Determination
Female
Gene Expression Regulation, Neoplastic
Humans
Kaplan-Meier Estimate
Lung Neoplasms
Male
Middle Aged
Multivariate Analysis
Mutation
Neoplasm Staging
Proportional Hazards Models
Randomized Controlled Trials as Topic
Retrospective Studies
Survival Rate
Treatment Outcome
authors with profiles
Noah Chan H Choi, M.D.
Raymond H Mak, M.D.
Elizabeth Healey Baldini, M.D.
David M Jackman, M.D.
Lecia Vandam Sequist, M.D.
Henning Willers, M.D.